All Stories

  1. PDE 10A inhibitors stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways

    Article • Pharmacology Research & Perspectives, June 2014, Wiley

    Dr Anton AHP Megens

  2. Discovery of a Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitor for the Potential Treatment of Schizophrenia

    Article • Journal of Medicinal Chemistry, May 2014, American Chemical Society (ACS)

    Dr Anton AHP Megens

  3. mGlu2 receptor-mediated modulation of conditioned avoidance behavior in rats

    Article • European Journal of Pharmacology, March 2014, Elsevier

    Dr Anton AHP Megens

  4. Pharmacology of JNJ-42314415, a Centrally Active Phosphodiesterase 10A (PDE10A) Inhibitor: A Comparison of PDE10A Inhibitors with D2 Receptor Blockers as Potential Antipsychotic Drugs

    Article • Journal of Pharmacology and Experimental Therapeutics, January 2014, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Anton AHP Megens

  5. Differential Interaction of Neuroleptics with Apomorphine-Induced Behavior in Rats as a Function of Changing Levels of Dopamine Receptor Stimulation

    Article • Journal of Pharmacology and Experimental Therapeutics, September 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Anton AHP Megens

  6. Pharmacological Characterization of JNJ-40068782, a New Potent, Selective, and Systemically Active Positive Allosteric Modulator of the mGlu2 Receptor and Its Radioligand [3H]JNJ-40068782

    Article • Journal of Pharmacology and Experimental Therapeutics, June 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Anton AHP Megens

  7. Discovery of 3-Cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): A Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor

    Article • Journal of Medicinal Chemistry, October 2012, American Chemical Society (ACS)

    Dr Anton AHP Megens

  8. Pharmacology of JNJ-37822681, a Specific and Fast-Dissociating D2 Antagonist for the Treatment of Schizophrenia

    Article • Journal of Pharmacology and Experimental Therapeutics, April 2012, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Anton AHP Megens

  9. Gavage-Related Reflux in Rats

    Article • Toxicologic Pathology, December 2010, SAGE Publications

    Dr Anton AHP Megens

  10. Impact of gavage dosing procedure and gastric content on adverse respiratory effects and mortality in rat toxicity studies

    Article • Journal of Applied Toxicology, November 2010, Wiley

    Dr Anton AHP Megens

  11. ChemInform Abstract: New 2-Substituted 1,2,3,4-Tetrahydrobenzofuro[3,2-c]pyridine Having Highly Active and Potent Central α2-Antagonistic Activity as Potential Antidepressants.

    Article • ChemInform, June 2010, Wiley

    Dr Anton AHP Megens

  12. ChemInform Abstract: Synthesis and Structure-Activity Relationship of 2-(Aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine Derivatives: A Novel Series of 5-HT2A/2C Receptor Antagonists. Part 1.

    Article • ChemInform, May 2010, Wiley

    Dr Anton AHP Megens

  13. ChemInform Abstract: Synthesis and Biological Evaluation of Imidazol-2-one and 2-Cyanoiminoimidazole Derivatives: Novel Series of PDE4 Inhibitors.

    Article • ChemInform, May 2010, Wiley

    Dr Anton AHP Megens

  14. ChemInform Abstract: Synthesis and Structure-Activity Relationship of 2-(Aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine Derivatives: A Novel Series of 5-HT2A/2C Receptor Antagonists. Part 2.

    Article • ChemInform, May 2010, Wiley

    Dr Anton AHP Megens

  15. Evaluation of serotonin-2A receptor occupancy with 123I-5-I-R91150 and single-photon emission tomography before and after low-dose pipamperone administration in the canine brain

    Article • Nuclear Medicine Communications, August 2008, Wolters Kluwer Health

    Dr Anton AHP Megens

  16. Pharmacokinetic–pharmacodynamic modeling of the effect of fluvoxamine on p-chloroamphetamine-induced behavior

    Article • European Journal of Pharmaceutical Sciences, November 2007, Elsevier

    Dr Anton AHP Megens

  17. Tricyclic isoxazolines: Identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and α2-adrenoceptor antagonism

    Article • Bioorganic & Medicinal Chemistry, June 2007, Elsevier

    Dr Anton AHP Megens

  18. Synthesis of 7-amino-3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazole derivatives displaying combined α2-adrenoceptor antagonistic and 5-HT reuptake inhibiting activities

    Article • Bioorganic & Medicinal Chemistry, July 2006, Elsevier

    Dr Anton AHP Megens

  19. Attentional performance of C57BL/6 and DBA/2 mice in the 5-choice serial reaction time task

    Article • Behavioural Brain Research, June 2006, Elsevier

    Dr Anton AHP Megens

  20. Preclinical Assessment of the Feasibility of Applying Controlled Release Oral Drug Delivery to a Lead Series of Atypical Antipsychotics

    Article • Journal of Pharmaceutical Sciences, April 2006, Elsevier

    Dr Anton AHP Megens

  21. Novel 2-N,N-Dimethylaminomethyl-2,3,3a,12b-tetrahydrodibenzo[b,f]furo [2,3-d]oxepin Derivatives Displaying Combined Norepinephrine Reuptake Inhibition and 5-HT2A/2C Receptor Antagonism.

    Article • ChemInform, October 2005, Wiley

    Dr Anton AHP Megens

  22. Synthesis of 2-N,N-Dimethylaminomethyl-2,3,3a,12b-tetrahydrodibenzo[b,f]furo [2,3-d]oxepine Derivatives as Potential Anxiolytic Agents. Part 2. Substitutions by Methyl Groups on the Tetrahydrofuran Ring.

    Article • ChemInform, August 2005, Wiley

    Dr Anton AHP Megens

  23. Novel 2-N,N-dimethylaminomethyl-2,3,3a,12b-tetrahydrodibenzo[b,f]furo[2,3-d]oxepin derivatives displaying combined norepinephrine reuptake inhibition and 5-HT2A/2C receptor antagonism

    Article • Bioorganic & Medicinal Chemistry Letters, June 2005, Elsevier

    Dr Anton AHP Megens

  24. Synthesis of 2-N,N-dimethylaminomethyl-2,3,3a,12b-tetrahydrodibenzo[b,f]furo[2,3-d]oxepine derivatives as potential anxiolytic agents. Part 2: substitutions by methyl groups on the tetrahydrofuran ring

    Article • Il Farmaco, March 2005, Elsevier

    Dr Anton AHP Megens

  25. Norpiperidine Imidazoazepines as a New Class of Potent, Selective, and Nonsedative H1 Antihistamines

    Article • Journal of Medicinal Chemistry, December 2004, American Chemical Society (ACS)

    Dr Anton AHP Megens

  26. Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test

    Article • Psychopharmacology, December 2004, Springer Science + Business Media

    Dr Anton AHP Megens

  27. Discovery of a New Series of Centrally Active Tricyclic Isoxazoles Combining Serotonin (5-HT) Reuptake Inhibition with α2-Adrenoceptor Blocking Activity

    Article • Journal of Medicinal Chemistry, November 2004, American Chemical Society (ACS)

    Dr Anton AHP Megens

  28. Discovery of New Tetracyclic Tetrahydrofuran Derivatives as Potential Broad-Spectrum Psychotropic Agents

    Article • Journal of Medicinal Chemistry, September 2004, American Chemical Society (ACS)

    Dr Anton AHP Megens

  29. Synthesis of 2-N,N-Dimethylaminomethyl-2,3,3a,12b-tetrahydrodibenzo[b,f]furo [2,3-d]oxepin Derivatives as Potential Anxiolytic Agents.

    Article • ChemInform, July 2004, Wiley

    Dr Anton AHP Megens

  30. Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and α2-adrenoceptor antagonistic activities. Part 2: Further exploration on the cinnamyl moiety

    Article • Bioorganic & Medicinal Chemistry Letters, June 2004, Elsevier

    Dr Anton AHP Megens

  31. Synthesis and structure–activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT2A/2C receptor antagonists

    Article • Bioorganic & Medicinal Chemistry Letters, June 2004, Elsevier

    Dr Anton AHP Megens

  32. Synthesis of 2-N,N-Dimethylaminomethyl-2,3,3a,12b-tetrahydrodibenzo-[b,f]furo[2,3-d]oxepin Derivatives as Potential Anxiolytic Agents

    Article • Chemical and Pharmaceutical Bulletin, January 2004, Pharmaceutical Society of Japan

    Dr Anton AHP Megens

  33. Synthesis of 3a,4-Dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, Displaying Combined 5-HT Uptake Inhibiting and α2-Adrenoceptor Antagonistic Activities: A Novel Series of Potential Antidepressants.

    Article • ChemInform, December 2003, Wiley

    Dr Anton AHP Megens

  34. Synthesis of 3a,4-dihydro-3H-[1]benzopyrano[4,3-c]isoxazoles, displaying combined 5-HT uptake inhibiting and α2-adrenoceptor antagonistic activities: a novel series of potential antidepressants

    Article • Bioorganic & Medicinal Chemistry Letters, August 2003, Elsevier

    Dr Anton AHP Megens

  35. Functional study of rat 5-HT2A receptors using antisense oligonucleotides

    Article • Journal of Neurochemistry, May 2003, Wiley

    Dr Anton AHP Megens

  36. The Atypical Antipsychotics Risperidone, Clozapine and Olanzapine Differ Regarding Their Sedative Potency in Rats

    Article • Neuropsychobiology, January 2003, Karger Publishers

    Dr Anton AHP Megens

  37. The Differential Effects of Atypical Antipsychotics on Prolactin Elevation Are Explained by Their Differential Blood-Brain Disposition: A Pharmacological Analysis in Rats

    Article • Journal of Pharmacology and Experimental Therapeutics, September 2002, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Anton AHP Megens

  38. Pharmacological Profile of (2R-trans)-4-[1-[3,5-bis(Trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an Orally and Centrally Active Neurokinin-1 Receptor Antagonist

    Article • Journal of Pharmacology and Experimental Therapeutics, August 2002, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Anton AHP Megens

  39. Role of 5-HT2 receptors in the tryptamine-induced 5-HT syndrome in rats

    Article • Behavioural Pharmacology, July 2002, Wolters Kluwer Health

    Dr Anton AHP Megens

  40. Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors

    Article • Bioorganic & Medicinal Chemistry Letters, February 2002, Elsevier

    Dr Anton AHP Megens

  41. Synthesis and structure–activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT2A/2C receptor antagonists. Part 1

    Article • Bioorganic & Medicinal Chemistry Letters, January 2002, Elsevier

    Dr Anton AHP Megens

  42. Synthesis and structure–Activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT2A/2C receptor antagonists. Part 2

    Article • Bioorganic & Medicinal Chemistry Letters, January 2002, Elsevier

    Dr Anton AHP Megens

  43. New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2- c ]pyridine having highly active and potent central α 2 -antagonistic activity as potential antidepressants

    Article • Bioorganic & Medicinal Chemistry Letters, January 2000, Elsevier

    Dr Anton AHP Megens

  44. The constipation-inducing potential of morphine and transdermal fentanyl

    Article • European Journal of Pain, December 1999, Wiley

    Dr Anton AHP Megens

  45. Does phenylethylamine act as an endogenous amphetamine in some patients?

    Article • The International Journal of Neuropsychopharmacology, September 1999, Oxford University Press (OUP)

    Dr Anton AHP Megens

  46. Comparison of the Analgesic and Intestinal Effects of Fentanyl and Morphine in Rats

    Article • Journal of Pain and Symptom Management, April 1998, Elsevier

    Dr Anton AHP Megens

  47. Carlos J.E. Niemegeers (1927–1997)

    Article • Psychopharmacology, December 1997, Springer Science + Business Media

    Dr Anton AHP Megens

  48. 5 Risperidone and related 5HT2/D2 antagonists: A new type of antipsychotic agent?

    Article • Progress in Medicinal Chemistry, January 1996, Elsevier

    Dr Anton AHP Megens

  49. In vivo pharmacological profile of 9-hydroxyrisperidone, the major metabolite of the novel antipsychotic risperidone

    Article • Drug Development Research, December 1994, Wiley

    Dr Anton AHP Megens

  50. Survey on the pharmacodynamics of the new antipsychotic risperidone

    Article • Psychopharmacology, February 1994, Springer Science + Business Media

    Dr Anton AHP Megens

  51. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat

    Article • Psychopharmacology, February 1994, Springer Science + Business Media

    Dr Anton AHP Megens

  52. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography

    Article • Brain Research, December 1993, Elsevier

    Dr Anton AHP Megens

  53. Loperamide

    Article • Digestive Diseases and Sciences, June 1993, Springer Science + Business Media

    Dr Anton AHP Megens

  54. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors

    Article • Psychopharmacology, March 1993, Springer Science + Business Media

    Dr Anton AHP Megens

  55. Die Pharmakologie von Risperidon

    Article • January 1993, Springer Science + Business Media

    Dr Anton AHP Megens

  56. Levocabastine: Pharmacological profile of a highly effective inhibitor of allergic reactions

    Article • January 1992

    Dr Anton AHP Megens

  57. Antipsychotic profile and side-effect liability of haloperidol, risperidone, and ocaperidone as predicted from their differential interaction with amphetamine in rats

    Article • Drug Development Research, January 1992, Wiley

    Dr Anton AHP Megens

  58. Comparison of the in vivo pharmacological profiles of sabeluzole and its enantiomers

    Article • Drug Development Research, January 1991, Wiley

    Dr Anton AHP Megens

  59. Tryptamine-induced hyperreactivity to apomorphine in rats. Effects of haloperidol, risperidone, ritanserin and R 79 598

    Article • European Journal of Pharmacology, July 1990, Elsevier

    Dr Anton AHP Megens

  60. Pharmacological profile of the new benzisoxazolyl neuroleptic R 79 598

    Article • European Journal of Pharmacology, July 1990, Elsevier

    Dr Anton AHP Megens

  61. Behavioral disinhibition after risperidone in amphetamine challenged rats: a comparison with haloperidol

    Article • European Journal of Pharmacology, July 1990, Elsevier

    Dr Anton AHP Megens

  62. Effects of the new benzisoxazolyl neuroleptic R 79 598 on spontaneous motility in rats: a comparison with haloperidol and risperidone

    Article • European Journal of Pharmacology, July 1990, Elsevier

    Dr Anton AHP Megens

  63. Normalization of small intestinal propulsion with loperamide-like antidiarrheals in rats

    Article • European Journal of Pharmacology, March 1990, Elsevier

    Dr Anton AHP Megens

  64. Interaction of haloperidol and risperidone (R 64 766) with amphetamine-induced motility changes in rats

    Article • Drug Development Research, January 1989, Wiley

    Dr Anton AHP Megens

  65. Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: a comparison with haloperidol

    Article • Psychopharmacology, August 1988, Springer Science + Business Media

    Dr Anton AHP Megens

  66. Pharmacological profile of ritanserin: A very specific central serotonin S2-antagonist

    Article • Drug Development Research, January 1988, Wiley

    Dr Anton AHP Megens

  67. Behavioural activity of rats measured by a new method based on the piezo-electric principle

    Article • Psychopharmacology, November 1987, Springer Science + Business Media

    Dr Anton AHP Megens

  68. Further validation of in vivo and in vitro pharmacological procedures for assessing the α2/α1-selectivity of test compounds: (1) α-adrenoceptor antagonists

    Article • European Journal of Pharmacology, September 1986, Elsevier

    Dr Anton AHP Megens

  69. Further validation of in vivo and in vitro pharmacological procedures for assessing the α2/α1-selectivity of test compounds: (2) α-adrenoceptor agonists

    Article • European Journal of Pharmacology, September 1986, Elsevier

    Dr Anton AHP Megens

  70. Non-antidopaminergic, non-cholinergic stimulation of gastric emptying with cisapride (R 51 619) in rats

    Article • Drug Development Research, May 1986, Wiley

    Dr Anton AHP Megens

  71. Antagonism of the antidiarrhoeal effect of clonidine and the lethal effect of noradrenaline in rats: a reliable procedure to evaluate the in-vivo α1- and α2-blocking activity of drugs?

    Article • Journal of Pharmacy and Pharmacology, August 1984, Oxford University Press (OUP)

    Dr Anton AHP Megens

  72. Involvement of the septum in central dopamine-acetylcholine interactions in morphine-treated cats

    Article • Pharmacology Biochemistry and Behavior, May 1983, Elsevier

    Dr Anton AHP Megens

  73. Intraseptally injected opiate agents: Effects on morphine-induced behaviour of cats

    Article • Pharmacology Biochemistry and Behavior, August 1982, Elsevier

    Dr Anton AHP Megens

  74. Presence of a particular subpopulation of dopamine receptors within the septal nuclei: a behavioural study on cats

    Article • European Journal of Pharmacology, May 1981, Elsevier

    Dr Anton AHP Megens

  75. Effects of intraseptal administration of cholinergic agents on morphine-induced behavior of cats

    Article • Psychopharmacology, November 1979, Springer Science + Business Media

    Dr Anton AHP Megens

  76. Morphine and its biphasic influence upon pharmacologically distinct dopaminergic systems within the feline caudate nucleus: A behavioural study

    Article • European Journal of Pharmacology, March 1978, Elsevier

    Dr Anton AHP Megens

  77. Functional antagonism between dopamine and noradrenaline within the caudate nucleus of cats: A phenomenon of rhythmically changing susceptibility

    Article • Psychopharmacology, January 1978, Springer Science + Business Media

    Dr Anton AHP Megens

  78. Site of action of development of partial tolerance to morphine in cats

    Article • Psychoneuroendocrinology, January 1977, Elsevier

    Dr Anton AHP Megens